<p>新泽西州伊瑟林，2025 年 12 月 26 日（环球新闻通讯社）——Outlook Therapeutics, Inc.（纳斯达克：OTLK），一家专注于提升贝伐单抗在视网膜疾病治疗中标准护理的生物制药公司，今天宣布，自 2025 年 12 月 19 日起，Outlook Therapeutics, Inc.董事会薪酬委员会向两名新员工授予了购买共计 150,000 股 Outlook Therapeutics 普通股的股票期权，行使价格为每股 2.01 美元。</p>
<p>上述奖励是根据纳斯达克上市规则 5635(c)(4) 作为员工入职公司的诱因而授予的。</p>
<p><strong>关于 Outlook Therapeutics, Inc.</strong></p>
<p>Outlook Therapeutics 是一家生物制药公司，专注于 ONS-5010/LYTENAVA™（贝伐单抗-vikg，贝伐单抗 gamma）的开发和商业化，以提升贝伐单抗在视网膜疾病治疗中的标准护理。LYTENAVA™（贝伐单抗 gamma）是首个获得欧洲委员会和 MHRA 批准用于治疗湿性年龄相关性黄斑变性（湿性 AMD）的贝伐单抗眼用制剂。Outlook Therapeutics 已在德国和英国开始 LYTENAVA™（贝伐单抗 gamma）用于湿性 AMD 的商业发布。</p>
<p>在美国，ONS-5010/LYTENAVA™（贝伐单抗-vikg）仍处于研究阶段。如果在美国获得批准，ONS-5010/LYTENAVA™将成为首个获批用于视网膜适应症（包括湿性 AMD）的贝伐单抗眼用制剂。</p>
<p><strong>投资者咨询：</strong> Jenene Thomas</p>
<p>首席执行官</p>
<p>JTC Team, LLC</p>
<p>电话：908.824.0775</p>
<p>OTLK@jtcir.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qZ3pPQ00zTXpNMU5EQTFJekl3TWpnNE1qST0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qZ3pPQ00zTXpNMU5EQTFJekl3TWpnNE1qST0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NmI4ODU1ZmItNTAyNC00Yjg4LWEwMDctYTMxY2JkMWIxMGI3LTEwNDAzOTMtMjAyNS0xMi0yNi1lbg==/tiny/Outlook-Therapeutics-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NmI4ODU1ZmItNTAyNC00Yjg4LWEwMDctYTMxY2JkMWIxMGI3LTEwNDAzOTMtMjAyNS0xMi0yNi1lbg==/tiny/Outlook-Therapeutics-Inc-.png"/></p>

OTLK

<p>Outlook Therapeutics 宣布新的就业诱因奖励，将于 2025 年 12 月 19 日生效。公司的薪酬委员会向两名新员工授予了以每股 2.01 美元购买 150,000 股股票的期权。这些奖励是根据 NASDAQ 上市规则 5635(c)(4) 作为就业诱因给予的</p>

<p>ISELIN, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that effective December 19, 2025, the Outlook Therapeutics, Inc. Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 150,000 shares of Outlook Therapeutics common stock with a per share exercise price of $2.01 per share to two new employees.</p>
<div class="lb-trans"><p>新泽西州伊瑟林，2025 年 12 月 26 日（环球新闻通讯社）——Outlook Therapeutics, Inc.（纳斯达克：OTLK），一家专注于提升贝伐单抗在视网膜疾病治疗中标准护理的生物制药公司，今天宣布，自 2025 年 12 月 19 日起，Outlook Therapeutics, Inc.董事会薪酬委员会向两名新员工授予了购买共计 150,000 股 Outlook Therapeutics 普通股的股票期权，行使价格为每股 2.01 美元。</p>
</div><p>The above-described awards were granted as an inducement material to the employees entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).</p>
<div class="lb-trans"><p>上述奖励是根据纳斯达克上市规则 5635(c)(4) 作为员工入职公司的诱因而授予的。</p>
</div><p><strong>About Outlook Therapeutics, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Outlook Therapeutics, Inc.</strong></p>
</div><p>Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retinal diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD (wet age-related macular degeneration). Outlook Therapeutics commenced the commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the treatment of wet AMD.</p>
<div class="lb-trans"><p>Outlook Therapeutics 是一家生物制药公司，专注于 ONS-5010/LYTENAVA™（贝伐单抗-vikg，贝伐单抗 gamma）的开发和商业化，以提升贝伐单抗在视网膜疾病治疗中的标准护理。LYTENAVA™（贝伐单抗 gamma）是首个获得欧洲委员会和 MHRA 批准用于治疗湿性年龄相关性黄斑变性（湿性 AMD）的贝伐单抗眼用制剂。Outlook Therapeutics 已在德国和英国开始 LYTENAVA™（贝伐单抗 gamma）用于湿性 AMD 的商业发布。</p>
</div><p>In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.</p>
<div class="lb-trans"><p>在美国，ONS-5010/LYTENAVA™（贝伐单抗-vikg）仍处于研究阶段。如果在美国获得批准，ONS-5010/LYTENAVA™将成为首个获批用于视网膜适应症（包括湿性 AMD）的贝伐单抗眼用制剂。</p>
</div><p><strong>Investor Inquiries:</strong> Jenene Thomas</p>
<div class="lb-trans"><p><strong>投资者咨询：</strong> Jenene Thomas</p>
</div><p>Chief Executive Officer</p>
<div class="lb-trans"><p>首席执行官</p>
</div><p>JTC Team, LLC</p>
<div class="lb-trans"><p>JTC Team, LLC</p>
</div><p>T: 908.824.0775</p>
<div class="lb-trans"><p>电话：908.824.0775</p>
</div><p>OTLK@jtcir.com</p>
<div class="lb-trans"><p>OTLK@jtcir.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qZ3pPQ00zTXpNMU5EQTFJekl3TWpnNE1qST0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxNjgzOCM3MzM1NDA1IzIwMjg4MjI="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NmI4ODU1ZmItNTAyNC00Yjg4LWEwMDctYTMxY2JkMWIxMGI3LTEwNDAzOTMtMjAyNS0xMi0yNi1lbg==/tiny/Outlook-Therapeutics-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/NmI4ODU1ZmItNTAyNC00Yjg4LWEwMDctYTMxY2JkMWIxMGI3LTEwNDAzOTMtMjAyNS0xMi0yNi1lbg==/tiny/Outlook-Therapeutics-Inc-.png"/></p>

Outlook Therapeutics 宣布新的就业激励授予 | OTLK 股票新闻